CD274 and non-small cell lung carcinoma: However, a recent review by Vrankar et al reported the “symptomatic pseudoprogression” in eight NSCLC patients treated with anti‐PD‐1/PD‐L1 therapy.42 These eight patients experienced psuedoprogression accompanied with clinical deterioration, followed by clinical benefit after 4‐20 weeks after treatment onset.